MCH ANALYSIS RESEARCHMain site ↗
Information Technology

Electronic Equipment & Instruments

8 companies under coverage.

Coverage

Electronic Equipment & Instruments


Equity Research

Vontier Corp (VNT)

BUY. 12-month probability-weighted target $41 (+28% vs spot). P/E Multiple explains 60% of Monte Carlo outcome variance.

VNTEquity ResearchMonte Carlo
10 October 2026Rating: BUY · Fair value vs price +14.7%
Equity Research

Cognex Corporation (CGNX)

HOLD. 12-month probability-weighted target $62 (-2% vs spot). P/E Multiple explains 77% of Monte Carlo outcome variance.

CGNXEquity ResearchMonte Carlo
10 October 2026Rating: HOLD · Fair value vs price -10.3%
Equity Research

Teledyne Technologies Incorporated (TDY)

HOLD. 12-month probability-weighted target $603 (-2% vs spot). P/E Multiple explains 64% of Monte Carlo outcome variance.

TDYEquity ResearchMonte Carlo
10 October 2026Rating: HOLD · Fair value vs price -13.8%
Equity Research

Crane NXT Co (CXT)

HOLD. 12-month probability-weighted target $51 (+1% vs spot). P/E Multiple explains 55% of Monte Carlo outcome variance.

CXTEquity ResearchMonte Carlo
10 October 2026Rating: HOLD · Fair value vs price -16.6%
Equity Research

Roper Technologies Inc (ROP)

HOLD. 12-month probability-weighted target $324 (-11% vs spot). P/E Multiple explains 75% of Monte Carlo outcome variance.

ROPEquity ResearchMonte Carlo
10 October 2026Rating: HOLD · Fair value vs price -21.2%
Equity Research

Keysight Technologies Inc (KEYS)

SELL. 12-month probability-weighted target $334 (-13% vs spot). P/E Multiple explains 81% of Monte Carlo outcome variance.

KEYSEquity ResearchMonte Carlo
10 October 2026Rating: SELL · Fair value vs price -22.1%
Equity Research

Zebra Technologies Corporation (ZBRA)

SELL. 12-month probability-weighted target $248 (-36% vs spot). P/E Multiple explains 63% of Monte Carlo outcome variance.

ZBRAEquity ResearchMonte Carlo
10 October 2026Rating: SELL · Fair value vs price -40.6%
Equity Research

Novanta Inc (NOVT)

Rating suspended since 2026-09-21 — valuation multiple under review. The rating, price target and expected return are withheld until the name is re-valued; the research on the report page predates the review.

NOVTEquity ResearchMonte Carlo
10 October 2026Rating: N/A
MCH ANALYSIS · All research · Research, not personal financial advicemchadvisoryservices.com ↗ · Research Standard v4 (decision-level) · Research OS ros-1.20.0 · US-listed

MCH Analysis is a general investment-research publication of MCH Advisory (Pty) Ltd. It is not personal financial advice and does not take your circumstances into account. MCH is not a licensed financial services provider or a registered investment adviser. Past performance, whether actual or simulated, does not predict future results. Subscriber Agreement | Privacy and Cookie Notice | Research Governance Policies